2566 The use and impact of rapid molecular testing for group A streptococcus in a paediatric emergency department

<h3>Aims and Objectives</h3> The UK in the winter of 2022/23 experienced high rates of Group A Streptococcal disease (GAS) and viral co-circulation in the community with an increase in GAS-associated mortality. This resulted in high numbers of attendances to Emergency Departments (EDs) from concerned families putting further strain on already bursting EDs. The approval of a national interim guideline was announced to support clinical diagnosis &amp; appropriate use of antimicrobials. We describe the implementation of a rapid molecular test (ID NOWTM Strep A 2, Abbott) in a busy Paediatric ED. <h3>Method and Design</h3> In patients &lt;= 16years old presenting with symptoms/signs of possible GAS during Feb - April 2023, rapid molecular GAS testing was obtained alongside a throat culture, this was using FeverPAIN score as per NICE guideline NG 84. Patients &gt;3yrs in whom there was diagnostic uncertainty ie FeverPAIN 2/3 had a GAS POC and throat swab, those with FeverPAIN 4/5 were treated empirically and had a throat culture sent. <h3>Results and Conclusion</h3> During the study period we obtained 405 rapid molecular GAS tests in 400 patients (51% male). Average age was 4.5yr (SD=3.7). Out of all rapid molecular GAS tests, 266 (65.7%) were negative, 138 (34.1%) positive and 1 (0.2%) had invalid results. 362 patients (89.4%) also had a throat swab (gold standard test). Comparing the rapid molecular GAS test with throat culture results showed a sensitivity=96.8%, specificity=88.1%, Positive Predictive Value (PPV)= 74% and Negative Predictive Value (NPV)= 98.7%. Out of the 266 children with negative rapid molecular GAS test results, 164 (61.6%) did not receive antibiotic therapy. Implementation of rapid molecular GAS testing is feasible and practical in a busy ED setting. It can be used to aid rapid decision making at the bedside, meaning appropriate, prompt treatment for GAS without need to follow up on throat culture results – beneficial both for antimicrobial stewardship and patient care.

Authors

Institutions

Publication Details

Published
2024-09-30
DOI
https://doi.org/10.1136/emermed-2024-rcem.32
Primary Topic
Streptococcal Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

2566 The use and impact of rapid molecular testing for group A streptococcus in a paediatric emergency department

Beatriz Larrú, Shrouk Messahel, Charlotte Durand, Sarah Siner et al.
Streptococcal Infections and Treatments
article

2566 The use and impact of rapid molecular testing for group A streptococcus in a paediatric emergency department

Beatriz Larrú, Shrouk Messahel, Charlotte Durand, Sarah Siner, Kelly Mayes
article en

Abstract

<h3>Aims and Objectives</h3> The UK in the winter of 2022/23 experienced high rates of Group A Streptococcal disease (GAS) and viral co-circulation in the community with an increase in GAS-associated mortality. This resulted in high numbers of attendances to Emergency Departments (EDs) from concerned families putting further strain on already bursting EDs. The approval of a national interim guideline was announced to support clinical diagnosis &amp; appropriate use of antimicrobials. We describe the implementation of a rapid molecular test (ID NOWTM Strep A 2, Abbott) in a busy Paediatric ED. <h3>Method and Design</h3> In patients &lt;= 16years old presenting with symptoms/signs of possible GAS during Feb - April 2023, rapid molecular GAS testing was obtained alongside a throat culture, this was using FeverPAIN score as per NICE guideline NG 84. Patients &gt;3yrs in whom there was diagnostic uncertainty ie FeverPAIN 2/3 had a GAS POC and throat swab, those with FeverPAIN 4/5 were treated empirically and had a throat culture sent. <h3>Results and Conclusion</h3> During the study period we obtained 405 rapid molecular GAS tests in 400 patients (51% male). Average age was 4.5yr (SD=3.7). Out of all rapid molecular GAS tests, 266 (65.7%) were negative, 138 (34.1%) positive and 1 (0.2%) had invalid results. 362 patients (89.4%) also had a throat swab (gold standard test). Comparing the rapid molecular GAS test with throat culture results showed a sensitivity=96.8%, specificity=88.1%, Positive Predictive Value (PPV)= 74% and Negative Predictive Value (NPV)= 98.7%. Out of the 266 children with negative rapid molecular GAS test results, 164 (61.6%) did not receive antibiotic therapy. Implementation of rapid molecular GAS testing is feasible and practical in a busy ED setting. It can be used to aid rapid decision making at the bedside, meaning appropriate, prompt treatment for GAS without need to follow up on throat culture results – beneficial both for antimicrobial stewardship and patient care.

University of Liverpool (GB), Alder Hey Children's NHS Foundation Trust (GB), Alder Hey Children's Hospital (GB)
Good health and well-being
Openalex Percentile: Top 75%
Streptococcal Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.